Biopharma BD Report | Q2 2025
Gain actionable intelligence on Q2 2025 biopharma deals—from oncology partnerships and obesity investment to IPO and private funding trends.
This quarterly report from the Syneos Health Commercial Advisory team analyzes biopharmaceutical deal spend across M&A, partnerships and asset purchases. It offers a strategic snapshot of high-value transactions and evolving business development trends shaping the global pharmaceutical and biotech landscape.
Inside this report:
• Q2 biopharma deal volume and value trends
• Top M&A and partnership highlights
• Ongoing investment in obesity and autoimmune treatments
• IPO and private placement analysis amid a slowing US market
• Deal activity by development phase and therapeutic area
FIll out the form below to access the full report.
Related Content
Looking for exclusive insight?
